DERMATOMYOSITIS
Clinical trials for DERMATOMYOSITIS explained in plain language.
Never miss a new study
Get alerted when new DERMATOMYOSITIS trials appear
Sign up with your email to follow new studies for DERMATOMYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Four-Year trial tests promising drug for debilitating muscle diseases
Disease control ENROLLING_BY_INVITATIONThis study follows up on previous participants to check the long-term safety and effectiveness of efgartigimod injections for inflammatory muscle diseases like dermatomyositis and polymyositis. About 240 adults who completed an earlier trial will receive the treatment for up to 5…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New pill could control debilitating muscle and skin disease
Disease control OngoingThis study is testing whether an oral medication called brepocitinib can help adults with dermatomyositis, an autoimmune disease that causes muscle weakness and skin rashes. About 241 participants will receive either the active drug or a placebo pill for 52 weeks to see which gro…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE3 • Sponsor: Priovant Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New pill shows promise for rare muscle disease
Disease control OngoingThis study is testing whether a daily oral medication called GLPG3667 can help control dermatomyositis, a rare autoimmune disease that causes muscle weakness and skin rashes. About 40 adults with active dermatomyositis will take either the drug or a placebo for 24 weeks, followed…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: Galapagos NV • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for rare muscle disease? experimental drug enters testing
Disease control OngoingThis study is testing a new drug called empasiprubart to see if it is safe and can help control the symptoms of dermatomyositis, a rare autoimmune disease that causes muscle weakness and skin rashes. About 3 adults with active dermatomyositis will receive either the new drug or a…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: argenx • Aim: Disease control
Last updated Mar 19, 2026 14:56 UTC
-
Early, aggressive treatment could halt debilitating muscle disease
Disease control OngoingThis study is testing if adding a treatment called intravenous immunoglobulin (IVIg) to standard steroid therapy early in the course of inflammatory muscle diseases (myositis) leads to better and faster improvement. It involves 44 adults newly diagnosed with conditions like derma…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2, PHASE3 • Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Psoriasis pill tested for rare muscle disease
Disease control TerminatedThis study aimed to test if an oral medication called deucravacitinib, already approved for plaque psoriasis, could help adults with dermatomyositis or juvenile dermatomyositis who did not respond well to standard treatments. Participants would have taken the pill twice daily for…
Matched conditions: DERMATOMYOSITIS
Phase: PHASE2 • Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC